0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Ongoing and Proposed Trials |

Glycemic Control and the Risk for Coronary Heart Disease in Patients with Non-Insulin-dependent Diabetes Mellitus: The Finnish Studies

Markku Laakso, MD
[+] Article and Author Information

From the University of Kuopio, Finland. For the current author address, see end of text. Note: This article is one of a series of articles comprising an Annals of Internal Medicine supplement entitled “Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus: The Fifth Regenstrief Conference.” To view a complete list of the articles included in this supplement, please view its Table of Contents. Grant Support: From the Medical Research Council of the Academy of Finland. Requests for Reprints: Markku Laakso, MD, Department of Medicine, University of Kuopio 70210, Kuopio, Finland.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;124(1_Part_2):127-130. doi:10.7326/0003-4819-124-1_Part_2-199601011-00009
Text Size: A A A

Purpose: To review population-based studies that investigated the association and nature of association between glycemic control and the risk for coronary heart disease in patients with non–insulin-dependent diabetes mellitus (NIDDM).

Data Sources: Study 1 included 133 newly diagnosed patients with NIDDM from eastern Finland, who were 45 to 64 years of age at baseline. These patients were followed up to 10 years for cardiovascular mortality. Study 2 included 229 newly or previously diagnosed patients with NIDDM from eastern Finland, aged 65 to 74 years at baseline. These patients were followed up to 3.5 years for coronary heart disease mortality and all coronary heart disease events (mortality or nonfatal myocardial infarction).

Study Selection: Prospective, population-based studies that included indicators of glycemic control and the evaluation of coronary heart disease and cardiovascular risk.

Results: Study 1: 10-year cardiovascular mortality was significantly and linearly associated with glycemic control (fasting blood glucose and glycated hemoglobin A1 levels) independently of the mode of treatment. A high fasting blood glucose level significantly predicted cardiovascular mortality in multiple logistic regression analysis independently of other risk factors. Study 2: Glycated hemoglobin A1c was the most important single risk factor associated with coronary heart disease death or all coronary heart disease events. In multiple logistic regression analysis, glycated hemoglobin A1c was significantly associated with coronary heart disease death after adjustment for other cardiovascular risk factors.

Conclusions: Two prospective, population-based studies from Finland give evidence for the linear association of glycemic control with the risk for coronary heart disease in middle-aged and elderly patients with NIDDM.

Figures

Grahic Jump Location
Figure 1.
The 10-year cardiovascular mortality by tertiles of fasting blood glucose level at baseline in diet- and drug-treated patients with diabetes.

Low: 8.6 mmol/L or less; middle: 8.7 to 11.8 mmol/L; high: 11.9 mmol/L or more (5; adapted from the original figure with the permission of authors and Diabetologia).

Grahic Jump Location
Grahic Jump Location
Figure 2.
The 3.1c1c1c1c

5-year incidence of coronary heart disease deaths and all coronary heart disease events (coronary heart disease death or nonfatal myocardial infarction) by tertile of glycated hemoglobin A (GHbA ) level. Low: less than 6.0%; middle: 6.0% to 7.9%; high: greater than 7.9% (9; drawn on the basis of the original figure, with the permission of the authors and Diabetes). CHD equals coronary heart disease; GHbA equals glycated hemoglobin A .

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)